Search clinical trials for: Doublet (RAD001 and LBH589)

Total 1425 results

Seoul National University Hospital

Completed

RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

Korea, Republic of
Dana-Farber Cancer Institute
Novartis; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Glioma | Astrocytoma | Low-grade Glioma

United States
Massachusetts General Hospital
Novartis; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center

Completed

RAD001 in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Jenny C. Chang, MD
The Methodist Hospital Research Institute

Completed

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (NECTAR)

Breast Cancer | Triple Negative Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Metastatic Renal Cell Carcinoma

China
Asan Medical Center

Completed

RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression

Stomach Neoplasm

Korea, Republic of
Hellenic Cooperative Oncology Group
Novartis

Terminated

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

Gastrointestinal Tumors | Pancreatic Neuroendocrine Tumors | Pancreatic Tumors | Gastrointestinal Neuroendocrine Tumors

Greece
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Plexiform Neurofibroma Associated With Neurofibromatosis Type 1

Israel
Bayside Health

Unknown

Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Australia
Novartis Pharmaceuticals

Terminated

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Novartis Pharmaceuticals

Completed

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Lymphangioleiomyomatosis

France, United States, Italy
NYU Langone Health

Completed

Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

Neurofibromatosis Type 2 | Meningiomas | Vestibular Schwannomas

United States
Novartis Pharmaceuticals

Completed

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

Renal Cell Carcinoma

South Africa, Egypt, Saudi Arabia, Russian Federation, Lebanon, Thailand, Jordan, India, Tunisia, Algeria
Seoul National University Hospital

Completed

Study of RAD001 in Adenoid Cystic Carcinoma (ACCRAD001)

Adenoid Cystic Carcinoma

Korea, Republic of
Austin Health

Unknown

Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol (RADiChol)

Cholangiocarcinoma

Australia
Sheba Medical Center

Unknown

Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer

Prostate Cancer

Israel
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Terminated

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Non-Hodgkin's Lymphoma

United States
University of Erlangen-Nürnberg Medical School

Terminated

Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

Germany
Southern Europe New Drug Organization
Bayer; Novartis

Suspended

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Advanced Solid Tumors

Italy
Ankara Training and Research Hospital

Not yet recruiting

Is it Safe to Advance a Guidewire Through a Previously Placed Double j Stent?

Kidney Stone | Ureter Obstruction | Stent Complication

Turkey
KalVista Pharmaceuticals, Ltd.
Juvenile Diabetes Research Foundation

Completed

A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

Diabetic Macular Edema

United States
Daniel George, MD
Novartis; Pfizer

Completed

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma (Rad/Sutent)

Renal Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | Plasmacytosis

United States
Gamaleya Research Institute of Epidemiology and...

Completed

Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine "GamTBvac" Against the Tuberculosis. (GamTBvac)

Tuberculosis

Russian Federation
KalVista Pharmaceuticals, Ltd.

Completed

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Diabetic Macular Edema

United States
Eli Lilly and Company

Completed

Chemotherapy in Treating Patients With Lung Cancer (FRAME)

Non Small Cell Lung Cancer
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center; Massachusetts General Hospital; Novartis; MOUNT SINAI...

Completed

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Thyroid Cancer

United States
Novartis Pharmaceuticals

Completed

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

Belgium, Italy, Poland, Sweden, France
Novartis Pharmaceuticals

Completed

Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

Small-Cell Lung Cancer

United States, France
Mustafa Sahin
Novartis Pharmaceuticals; Autism Speaks; Tuberous Sclerosis Alliance; Seizure Tracker...

Completed

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) (TSC)

Tuberous Sclerosis Complex

United States
Linda C. Higgins
University of Texas Southwestern Medical Center

Terminated

Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

Kidney Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Erasmus Medical Center

Withdrawn

Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome (EVAMP)

Neoplasm Metastasis | Neoplastic Processes | Peutz-Jeghers Syndrome

Netherlands
Cancer Institute and Hospital, Chinese Academy...
Dizal Pharmaceuticals

Not yet recruiting

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) (JACKPOT33)

Non-Small-Cell Lung Cancer

China
Boston Children's Hospital
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Renal Angiomyolipoma

China
Novartis Pharmaceuticals

Completed

Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients (4EVERLUNG)

Lung Transplantation

Germany
Novartis Pharmaceuticals

Completed

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Neuroendocrine Tumors

Germany
Washington University School of Medicine

Completed

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Solid Tumor | Solid Malignancy

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
Erasmus Medical Center
Utrecht University

Unknown

Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex (RAPIT)

Tuberous Sclerosis Complex | TSC Related Cognitive Disability | TSC Related Autism | TSC Related Learning Problems

Netherlands
Mercy Medical Center

Completed

Evaluation of a Double Balloon Interventional Platform (DiLumen) for Complex Colonic ESD

Colonic Polyp

United States
Asan Medical Center

Completed

RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment

Stomach Neoplasm

Korea, Republic of
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Solid Tumor

Korea, Republic of
Baylor College of Medicine
Novartis Pharmaceuticals

Withdrawn

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Sturge Weber Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Sarcoma

United States
Medical University of South Carolina
Novartis Pharmaceuticals

Completed

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

Soft Tissue Sarcoma | Renal Cancer | Non Small Cell Lung Cancer (NSCLC)

United States
Deric M Park MD

Unknown

Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

Chordoma

United States
SCRI Development Innovations, LLC
Novartis; Onyx Therapeutics, Inc.

Completed

Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Novartis Pharmaceuticals

No longer available

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

Germany, Austria, Canada, Jordan, Norway, Sweden
Gangnam Severance Hospital

Recruiting

Efficacy of Hemi-double-stapling Technique

Periampullar Disease

Korea, Republic of

Search clinical trials for: Doublet (RAD001 and LBH589)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations